[go: up one dir, main page]

TR200201473T2 - Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri - Google Patents

Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri

Info

Publication number
TR200201473T2
TR200201473T2 TR2002/01473T TR200201473T TR200201473T2 TR 200201473 T2 TR200201473 T2 TR 200201473T2 TR 2002/01473 T TR2002/01473 T TR 2002/01473T TR 200201473 T TR200201473 T TR 200201473T TR 200201473 T2 TR200201473 T2 TR 200201473T2
Authority
TR
Turkey
Prior art keywords
oxazole
derivatives substituted
thiazole derivatives
hppar alpha
alpha activators
Prior art date
Application number
TR2002/01473T
Other languages
English (en)
Inventor
Lawrence Sierra Michael
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9928561.1A external-priority patent/GB9928561D0/en
Priority claimed from GB0003500A external-priority patent/GB0003500D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200201473T2 publication Critical patent/TR200201473T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

X1'in O veya S; R1 ve R2'nin bagimsiz olarak H, halojen, -CH3 ve-OCH3; n'nin 1 veya 2; X2'nin NH, NCH3 veya O; Y ve Z'den birinin N, ve digerinin O veya S; R3'ün fenil veya piridil olup (N'nin pozisyon 2 veya 3'te oldugu) ve tercihe göre bir veya birkaç halojen, NO2, NH2, CF3, OCF3, OC1-6 düz veya dalli alkil, C1-6 düz veya dalli alkil, alkenil veya alkinil oldugu ancak R3 piridil oldugunda N'nin ikamesiz oldugu; R4'ün CF3 veya CH3 oldugu bir formül(1): bilesimi, ve farmasötik olarak kabul edilebilir tuzlari, solvatlari ve hidrolize edilebilir esterleri. FORMÜL VAR.
TR2002/01473T 1999-12-02 2000-11-30 Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri TR200201473T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9928561.1A GB9928561D0 (en) 1999-12-02 1999-12-02 Chemical compounds
GB0003500A GB0003500D0 (en) 2000-02-15 2000-02-15 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200201473T2 true TR200201473T2 (tr) 2002-09-23

Family

ID=26243654

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2004/01772T TR200401772T4 (tr) 1999-12-02 2000-11-30 hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri.
TR2002/01473T TR200201473T2 (tr) 1999-12-02 2000-11-30 Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2004/01772T TR200401772T4 (tr) 1999-12-02 2000-11-30 hPPAR alfa aktivatörleri olarak ikame edilmiş oksazol ve tiyazol türevleri.

Country Status (27)

Country Link
US (1) US6518290B1 (tr)
EP (1) EP1244642B1 (tr)
JP (1) JP3884290B2 (tr)
KR (1) KR100706735B1 (tr)
CN (1) CN1184215C (tr)
AR (1) AR035631A1 (tr)
AT (1) ATE265442T1 (tr)
AU (1) AU758758B2 (tr)
BR (1) BR0016067A (tr)
CA (1) CA2393190A1 (tr)
CO (1) CO5251452A1 (tr)
CZ (1) CZ20021903A3 (tr)
DE (1) DE60010333T2 (tr)
DK (1) DK1244642T3 (tr)
ES (1) ES2219423T3 (tr)
GC (1) GC0000215A (tr)
HK (1) HK1047435B (tr)
HU (1) HUP0203532A3 (tr)
IL (2) IL149582A0 (tr)
MX (1) MXPA02005456A (tr)
NO (1) NO323135B1 (tr)
PE (1) PE20011010A1 (tr)
PL (1) PL356772A1 (tr)
PT (1) PT1244642E (tr)
TR (2) TR200401772T4 (tr)
TW (1) TW555753B (tr)
WO (1) WO2001040207A1 (tr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317885B1 (it) * 2000-08-01 2003-07-15 Sigma Tau Ind Farmaceuti Uso di fibrati per la preparazione di un medicamento utile neltrattamento dell'insufficienza cardiaca congestizia.
AU2001277723A1 (en) * 2000-08-11 2002-02-25 Nippon Chemiphar Co., Ltd. Ppardelta activators
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
US7105551B2 (en) * 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1345916A1 (en) 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0113232D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical process
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
GB0113233D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
MXPA04001258A (es) 2001-08-10 2005-06-06 Nippon Chemiphar Co Activador para el receptor d que responde al proliferador de peroxisoma.
HN2002000266A (es) * 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
AU2003224632A1 (en) * 2002-03-01 2003-09-16 Smithkline Beecham Corporation Hppars activators
KR100474202B1 (ko) * 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
GB0214139D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
AU2003241579B9 (en) 2002-06-19 2009-07-30 Eli Lilly And Company Amide linker peroxisome proliferator activated receptor modulators
US7273866B2 (en) 2002-12-20 2007-09-25 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as KCNQ modulators
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
EP1597248B1 (en) * 2003-02-14 2007-12-26 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
DE10331496A1 (de) * 2003-07-01 2005-01-27 Bayer Cropscience Ag Verfahren zum Herstellen von Difluoracetessigsäurealkylestern
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
US7541475B2 (en) 2003-07-30 2009-06-02 Abbott Laboratories Substituted thiazoles
TW200526588A (en) * 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
JPWO2005095364A1 (ja) * 2004-03-30 2008-02-21 第一三共株式会社 フェノキシ酢酸誘導体及びそれを用いた医薬
JP2007230868A (ja) * 2004-03-30 2007-09-13 Dai Ichi Seiyaku Co Ltd 二環性化合物及びそれを用いた医薬
DE102004016845A1 (de) * 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
WO2005097076A2 (en) * 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
JP2007284352A (ja) * 2004-08-05 2007-11-01 Dai Ichi Seiyaku Co Ltd ピラゾール誘導体
BRPI0515015A (pt) * 2004-08-11 2008-07-01 Kyorin Seiyaku Kk derivado cìclico de ácido aminobenzóico; medicamento; agonista ppar(alpha); agonista duplo ppar(alpha), y; agonista duplo ppar(alpha), (delta); modulador ppar; agente lipìdeo; agente profilático ou terapêutico compreendendo pelo menos um dos derivados cìclicos de ácido aminobenzóico ou sal do mesmo farmacêuticamente aceitável
CA2597148A1 (en) * 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as ppar activators
EP1862464A4 (en) * 2005-03-23 2010-08-25 Kyorin Seiyaku Kk NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE
JP3795515B1 (ja) 2005-08-10 2006-07-12 善典 中川 半導体光電気化学セルの製造方法
RU2435764C2 (ru) 2006-04-18 2011-12-10 Ниппон Кемифар Ко., Лтд. АГЕНТ, АКТИВИРУЮЩИЙ РЕЦЕПТОР, АКТИВИРУЕМЫЙ ПРОЛИФЕРАТОРАМИ ПЕРОКСИСОМ δ
WO2008035359A2 (en) * 2006-06-12 2008-03-27 Cadila Healthcare Limited Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
PL2125711T3 (pl) 2007-03-08 2014-05-30 Albireo Ab Pochodne kwasy 3-fenylopropionowego oraz ich zastosowanie w leczeniu nieswoistego zapalenia jelit
ES2551095T3 (es) * 2007-07-19 2015-11-16 Lundbeck, H., A/S Amidas heterocíclicas de 5 miembros y compuestos relacionados
KR100882261B1 (ko) 2007-07-25 2009-02-06 삼성전기주식회사 인쇄회로기판의 제조 방법 및 장치
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
AU2009236877B2 (en) 2008-04-15 2014-01-23 Nippon Chemiphar Co., Ltd. Activator for peroxisome proliferator-activated receptor
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010071813A1 (en) * 2008-12-19 2010-06-24 Aryx Therapeutics, Inc. AGONISTS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR-α
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN109810071B (zh) * 2019-03-28 2023-04-21 中国科学院成都生物研究所 一种miRNA生物合成抑制剂
CN110803996B (zh) * 2019-11-13 2022-01-11 台州市创源工业技术有限公司 一种羟基苄胺的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
AU738134B2 (en) * 1997-10-02 2001-09-06 Sankyo Company Limited Amidocarboxylic acid derivatives
US6506757B1 (en) * 1998-03-10 2003-01-14 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient

Also Published As

Publication number Publication date
IL149582A (en) 2008-11-26
HUP0203532A2 (hu) 2003-02-28
TR200401772T4 (tr) 2004-09-21
US6518290B1 (en) 2003-02-11
EP1244642B1 (en) 2004-04-28
JP3884290B2 (ja) 2007-02-21
CA2393190A1 (en) 2001-06-07
PT1244642E (pt) 2004-09-30
PE20011010A1 (es) 2001-10-18
HUP0203532A3 (en) 2005-01-28
AU2003001A (en) 2001-06-12
NO323135B1 (no) 2007-01-08
WO2001040207A1 (en) 2001-06-07
DE60010333D1 (de) 2004-06-03
CN1184215C (zh) 2005-01-12
TW555753B (en) 2003-10-01
HK1047435B (en) 2004-11-26
PL356772A1 (en) 2004-07-12
NO20022467L (no) 2002-07-26
JP2003515597A (ja) 2003-05-07
KR20020058073A (ko) 2002-07-12
CO5251452A1 (es) 2003-02-28
AR035631A1 (es) 2004-06-23
EP1244642A1 (en) 2002-10-02
ES2219423T3 (es) 2004-12-01
MXPA02005456A (es) 2002-11-29
IL149582A0 (en) 2002-11-10
KR100706735B1 (ko) 2007-04-13
CZ20021903A3 (cs) 2003-01-15
CN1402716A (zh) 2003-03-12
ATE265442T1 (de) 2004-05-15
GC0000215A (en) 2006-03-29
HK1047435A1 (en) 2003-02-21
DK1244642T3 (da) 2004-08-16
DE60010333T2 (de) 2005-06-16
NO20022467D0 (no) 2002-05-24
AU758758B2 (en) 2003-03-27
BR0016067A (pt) 2002-08-06

Similar Documents

Publication Publication Date Title
TR200201473T2 (tr) Hppar alfa aktivatörleri olarak ikameli oksazol ve tiyazol türevleri
IL158818A0 (en) Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
CA2378183A1 (en) Antibacterial heterobicyclic substituted phenyl oxazolidinones
CA2396738A1 (en) Thiazole derivatives as active superoxide radical inhibitors
WO2000047580A3 (en) Phenyl urea and phenyl thiourea derivatives
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
EP1310494A4 (en) PPAR-DELTA ACTIVATORS
TR200200076T2 (tr) Oral yoldan aktif androjenler
TR200000736T2 (tr) İkame edilmiş kroman türevleri.
DE69821530D1 (de) Dihydrobenzifurane
WO2002028844A1 (en) Thiazole or oxazole derivatives
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
NO20062629L (no) Oksazolderivater av tetrackliner
MY132656A (en) Oxazol/thiazol-derivatives activators of the hppar-alpha receptor
WO2003011859A3 (en) Oxazolidinone derivatives as antibacterial agents
DE60013188D1 (de) Fungiizide 6-(trifluormethyl-phenyl)-triazolpyrimidine
TR200103332T2 (tr) 1-Triflorometil-4-hidroksi-7-piperidinil-aminometilkroman türevleri.
TR200001750T2 (tr) Nöro-koruyucu maddeler olarak yararlı yeni bileşikler.
GB0116966D0 (en) Anittumoral compounds
HUP0402149A2 (hu) Vízoldható fenil-piridazin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
NO20001228L (no) Fremgangsmate for fremstilling av N-(5-(difenylfosfinoylmetyl)-4-(4-fluorfenyl)-6-isopropylpyrimidin-2-yl)-N-metylmetansulfonamid
NO941830D0 (no) Karboksamid-derivater, deres fremstilling og anvendelse som terapeutika